Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH

Andrew V Schally, Haibo Wang, Jinlin He, Renzhi Cai, Wei Sha, Petra Popovics, Roberto Perez, Irving Vidaurre, Xianyang Zhang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The effects of the growth hormone-releasing hormone (GHRH) agonist MR409 on various human cancer cells were investigated. In H446 small cell lung cancer (SCLC) and HCC827 and H460 (non-SCLC) cells, MR409 promoted cell viability, reduced cell apoptosis, and induced the production of cellular cAMP in vitro. Western blot analyses showed that treatment of cancer cells with MR409 up-regulated the expression of cyclins D1 and D2 and cyclin-dependent kinases 4 and 6, down-regulated p27kip1, and significantly increased the expression of the pituitary-type GHRH receptor (pGHRH-R) and its splice-variant (SV1). Hence, in vitro MR409 exerts agonistic action on lung cancer cells in contrast to GHRH antagonists. However, in vivo, MR409 inhibited growth of lung cancers xenografted into nude mice. MR409 given s.c. at 5 μg/day for 4 to 8 weeks significantly suppressed growth of HCC827, H460, and H446 tumors by 48.2%, 48.7%, and 65.6%, respectively. This inhibition of tumor growth by MR409 was accompanied by the down-regulation of the expression of pGHRH-R and SV1 in the pituitary gland and tumors. Tumor inhibitory effects of MR409 in vivo were also observed in other human cancers, including gastric, pancreatic, urothelial, prostatic, mammary, and colorectal. This inhibition of tumor growth parallel to the down-regulation of GHRH-Rs is similar and comparable to the suppression of sex hormone-dependent cancers after the down-regulation of receptors for luteinizing hormone-releasing hormone (LHRH) by LHRH agonists. Further oncological investigations with GHRH agonists are needed to elucidate the underlying mechanisms.

Original languageEnglish (US)
Pages (from-to)12028-12033
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number47
DOIs
StatePublished - Nov 20 2018

Fingerprint

Growth Hormone-Releasing Hormone
Neoplasms
Down-Regulation
Growth
Pituitary Hormone-Regulating Hormone Receptors
Lung Neoplasms
Cyclin-Dependent Kinase 6
Cyclin D2
Cyclin-Dependent Kinase 4
LHRH Receptors
Hormone Antagonists
Cyclin D1
Small Cell Lung Carcinoma
Gonadal Steroid Hormones
Pituitary Neoplasms
Pituitary Gland
somatotropin releasing hormone receptor
Nude Mice
Gonadotropin-Releasing Hormone
Non-Small Cell Lung Carcinoma

Keywords

  • GHRH agonists
  • GHRH antagonists
  • GHRH receptors
  • Lung cancers
  • Signaling pathways

ASJC Scopus subject areas

  • General

Cite this

Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. / Schally, Andrew V; Wang, Haibo; He, Jinlin; Cai, Renzhi; Sha, Wei; Popovics, Petra; Perez, Roberto; Vidaurre, Irving; Zhang, Xianyang.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 47, 20.11.2018, p. 12028-12033.

Research output: Contribution to journalArticle

Schally, Andrew V ; Wang, Haibo ; He, Jinlin ; Cai, Renzhi ; Sha, Wei ; Popovics, Petra ; Perez, Roberto ; Vidaurre, Irving ; Zhang, Xianyang. / Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. In: Proceedings of the National Academy of Sciences of the United States of America. 2018 ; Vol. 115, No. 47. pp. 12028-12033.
@article{9750bf359ae74beaa4858cfa2edf9077,
title = "Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH",
abstract = "The effects of the growth hormone-releasing hormone (GHRH) agonist MR409 on various human cancer cells were investigated. In H446 small cell lung cancer (SCLC) and HCC827 and H460 (non-SCLC) cells, MR409 promoted cell viability, reduced cell apoptosis, and induced the production of cellular cAMP in vitro. Western blot analyses showed that treatment of cancer cells with MR409 up-regulated the expression of cyclins D1 and D2 and cyclin-dependent kinases 4 and 6, down-regulated p27kip1, and significantly increased the expression of the pituitary-type GHRH receptor (pGHRH-R) and its splice-variant (SV1). Hence, in vitro MR409 exerts agonistic action on lung cancer cells in contrast to GHRH antagonists. However, in vivo, MR409 inhibited growth of lung cancers xenografted into nude mice. MR409 given s.c. at 5 μg/day for 4 to 8 weeks significantly suppressed growth of HCC827, H460, and H446 tumors by 48.2{\%}, 48.7{\%}, and 65.6{\%}, respectively. This inhibition of tumor growth by MR409 was accompanied by the down-regulation of the expression of pGHRH-R and SV1 in the pituitary gland and tumors. Tumor inhibitory effects of MR409 in vivo were also observed in other human cancers, including gastric, pancreatic, urothelial, prostatic, mammary, and colorectal. This inhibition of tumor growth parallel to the down-regulation of GHRH-Rs is similar and comparable to the suppression of sex hormone-dependent cancers after the down-regulation of receptors for luteinizing hormone-releasing hormone (LHRH) by LHRH agonists. Further oncological investigations with GHRH agonists are needed to elucidate the underlying mechanisms.",
keywords = "GHRH agonists, GHRH antagonists, GHRH receptors, Lung cancers, Signaling pathways",
author = "Schally, {Andrew V} and Haibo Wang and Jinlin He and Renzhi Cai and Wei Sha and Petra Popovics and Roberto Perez and Irving Vidaurre and Xianyang Zhang",
year = "2018",
month = "11",
day = "20",
doi = "10.1073/pnas.1813375115",
language = "English (US)",
volume = "115",
pages = "12028--12033",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "47",

}

TY - JOUR

T1 - Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH

AU - Schally, Andrew V

AU - Wang, Haibo

AU - He, Jinlin

AU - Cai, Renzhi

AU - Sha, Wei

AU - Popovics, Petra

AU - Perez, Roberto

AU - Vidaurre, Irving

AU - Zhang, Xianyang

PY - 2018/11/20

Y1 - 2018/11/20

N2 - The effects of the growth hormone-releasing hormone (GHRH) agonist MR409 on various human cancer cells were investigated. In H446 small cell lung cancer (SCLC) and HCC827 and H460 (non-SCLC) cells, MR409 promoted cell viability, reduced cell apoptosis, and induced the production of cellular cAMP in vitro. Western blot analyses showed that treatment of cancer cells with MR409 up-regulated the expression of cyclins D1 and D2 and cyclin-dependent kinases 4 and 6, down-regulated p27kip1, and significantly increased the expression of the pituitary-type GHRH receptor (pGHRH-R) and its splice-variant (SV1). Hence, in vitro MR409 exerts agonistic action on lung cancer cells in contrast to GHRH antagonists. However, in vivo, MR409 inhibited growth of lung cancers xenografted into nude mice. MR409 given s.c. at 5 μg/day for 4 to 8 weeks significantly suppressed growth of HCC827, H460, and H446 tumors by 48.2%, 48.7%, and 65.6%, respectively. This inhibition of tumor growth by MR409 was accompanied by the down-regulation of the expression of pGHRH-R and SV1 in the pituitary gland and tumors. Tumor inhibitory effects of MR409 in vivo were also observed in other human cancers, including gastric, pancreatic, urothelial, prostatic, mammary, and colorectal. This inhibition of tumor growth parallel to the down-regulation of GHRH-Rs is similar and comparable to the suppression of sex hormone-dependent cancers after the down-regulation of receptors for luteinizing hormone-releasing hormone (LHRH) by LHRH agonists. Further oncological investigations with GHRH agonists are needed to elucidate the underlying mechanisms.

AB - The effects of the growth hormone-releasing hormone (GHRH) agonist MR409 on various human cancer cells were investigated. In H446 small cell lung cancer (SCLC) and HCC827 and H460 (non-SCLC) cells, MR409 promoted cell viability, reduced cell apoptosis, and induced the production of cellular cAMP in vitro. Western blot analyses showed that treatment of cancer cells with MR409 up-regulated the expression of cyclins D1 and D2 and cyclin-dependent kinases 4 and 6, down-regulated p27kip1, and significantly increased the expression of the pituitary-type GHRH receptor (pGHRH-R) and its splice-variant (SV1). Hence, in vitro MR409 exerts agonistic action on lung cancer cells in contrast to GHRH antagonists. However, in vivo, MR409 inhibited growth of lung cancers xenografted into nude mice. MR409 given s.c. at 5 μg/day for 4 to 8 weeks significantly suppressed growth of HCC827, H460, and H446 tumors by 48.2%, 48.7%, and 65.6%, respectively. This inhibition of tumor growth by MR409 was accompanied by the down-regulation of the expression of pGHRH-R and SV1 in the pituitary gland and tumors. Tumor inhibitory effects of MR409 in vivo were also observed in other human cancers, including gastric, pancreatic, urothelial, prostatic, mammary, and colorectal. This inhibition of tumor growth parallel to the down-regulation of GHRH-Rs is similar and comparable to the suppression of sex hormone-dependent cancers after the down-regulation of receptors for luteinizing hormone-releasing hormone (LHRH) by LHRH agonists. Further oncological investigations with GHRH agonists are needed to elucidate the underlying mechanisms.

KW - GHRH agonists

KW - GHRH antagonists

KW - GHRH receptors

KW - Lung cancers

KW - Signaling pathways

UR - http://www.scopus.com/inward/record.url?scp=85056760834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056760834&partnerID=8YFLogxK

U2 - 10.1073/pnas.1813375115

DO - 10.1073/pnas.1813375115

M3 - Article

VL - 115

SP - 12028

EP - 12033

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 47

ER -